CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published ahead of print on April 1, 2009
Clinical Journal of the American Society of Nephrology
© 2009 American Society of Nephrology
doi: 10.2215/CJN.04590908
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Press Release
Right arrow All Versions of this Article:
CJN.04590908v1
4/4/745    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hutchison, C. A.
Right arrow Articles by Cockwell, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hutchison, C. A.
Right arrow Articles by Cockwell, P.

Received September 10, 2008
Accepted on January 7, 2009

ORIGINAL ARTICLES

Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis

Colin A. Hutchison *{dagger}1, Arthur R. Bradwell {ddagger}, Mark Cook {sect}, Kolitha Basnayake *{dagger}, Supratik Basu ||, Stephen Harding , John Hattersley **, Neil D. Evans **, Mike J. Chappel **, Paul Sampson *, Lukas Foggensteiner *, Dwomoa Adu *, and Paul Cockwell *{dagger}

*Department of Nephrology and {sect}Department of Haematology, Queen Elizabeth Hospital, Birmingham; {dagger}Division of Medical Sciences and {ddagger}Division of Immunity and Infection, Medical School, University of Birmingham; ||Department of Haematology, New Cross Hospital, Wolverhampton; ¶The Binding Site Ltd., Birmingham; **School of Engineering, University of Warwick, Coventry, United Kingdom


1 To whom correspondence should be addressed. E-mail: c.a.hutchison{at}bham.ac.uk.


  Abstract

Background and objectives: Extended hemodialysis using a high cut-off dialyzer (HCO-HD) removes large quantities of free light chains in patients with multiple myeloma. However, the clinical utility of this method is uncertain. This study assessed the combination of chemotherapy and HCO-HD on serum free light chain concentrations and renal recovery in patients with myeloma kidney (cast nephropathy) and dialysis-dependent acute renal failure.

Design, setting, participants, & measurements: An open-label study of the relationship between free light chain levels and clinical outcomes in 19 patients treated with standard chemotherapy regimens and HCO-HD.

Results: There were sustained early reductions in serum free light chain concentrations (median 85% [range 50 to 97]) in 13 patients. These 13 patients became dialysis independent at a median of 27 d (range 13 to 120). Six patients had chemotherapy interrupted because of early infections and did not achieve sustained early free light chain reductions; one of these patients recovered renal function (at 105 d) the remaining 5 patients did not recover renal function. Patients who recovered renal function had a significantly improved survival (P < 0.012).

Conclusion: In dialysis-dependent acute renal failure secondary to myeloma kidney, patients who received uninterrupted chemotherapy and extended HCO-HD had sustained reductions in serum free light chain concentrations and recovered independent renal function.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the American Society of Nephrology.